May 16 |
Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection
|
May 16 |
Takeda’s dengue vaccine obtains WHO prequalification
|
May 15 |
Takeda dengue vaccine gets WHO clearance
|
May 14 |
Update: Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute
|
May 14 |
Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute
|
May 14 |
Scilex wins court approval for Takeda settlement
|
May 14 |
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
|
May 13 |
Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday?
|
May 13 |
Takeda shells out $100m to license AC Immune’s Phase II Alzheimer’s therapy
|
May 13 |
AC Immune rockets 47% on Alzheimer's therapy deal with Takeda
|